



UNIVERSITY of WASHINGTON

THE CHOICE INSTITUTE
UW SCHOOL OF PHARMACY



Director's Welcome

Dear Colleagues,

We are in unprecedented times and I am greatly appreciative of how the faculty are working tirelessly to teach remotely, support students and carry out their scholarship. I came back from my sabbatical and was not at all surprised to find that CHOICE didn't miss a beat while I was gone, thanks to the leadership of **Dave Veenstra** as the Interim Director. Winter Quarter is the recruiting season, and we are pleased to announce a great incoming cohort of PhD students and MS Fellows, thanks to the hard work of our faculty, and most importantly, **Marina Gano** to make all these processes flow smoothly. Below you will find a list of ongoing achievements by our students, faculty, and alumni. They continue to make us proud!

We have also opened a search for a tenure-track faculty position in Health Economics. Details can be found on [Interfolio](#).

A few upcoming keys dates for CHOICE Events to remember (further details to be announced soon):

May 8, 2020 – CHOICE Retreat, Seattle WA

May 18, 2020– CHOICE ISPOR Social, Orlando FL

However, given the COVID-19 situation, we will continue to pay close attention to developments locally and nationally and follow our School' and University's lead to decide on the fate of these events. We wish everyone a safe Spring and encourage necessary precautions to mitigate the spread of the COVID-19 virus.

Sincerely,
Anirban

INCREMENTAL THOUGHTS: CHOICE BLOG




Winter Quarter Updates

What's new in the CHOICE Institute this quarter



New Novel Framework for Valuing Health Outcomes

Introducing "Health Years in Total:" A Novel Framework for Valuing Health Outcomes in Cost-Effectiveness Analyses developed by CHOICE Researchers. [READ MORE.](#)



Join us at ISPOR!

We are pleased to invite you to our 2020 ISPOR Social Reception in Orlando, FL. Join us after dinner on Monday, May 18, for drinks, dessert, and the Disney's Magic Kingdom fireworks! [RSVP HERE.](#)



Welcome to the new PharmD/MS Cohort

We are pleased to announce the 2020-22 cohort of CHOICE MS Fellows who will start with us in July. Congratulations to the recruitment team for all their efforts. [READ MORE.](#)

Digital Diabetes Prevention Program & Cost Outcomes

In a recent publication in Population Health Management, **Douglas Barthold** and colleagues examined the effects of a digital diabetes prevention program on health care costs and utilization. Despite some improved health outcomes, program



participants showed no significant changes in their medical or prescription drug spending, and no significant changes in their use of inpatient, outpatient, and emergency department care. These changes were measured over a 24-month period, and it is possible that effects could occur long-term. Overall, the study demonstrates that health improvements may not always connect to measurable changes in costs and utilization, and is an important contribution to exploring the effects of prevention programs in real-world samples.

FULL ARTICLE



Publications and Achievements

SELECTED PUBLICATIONS:

Barthold D, Joyce G, Diaz Brinton R, Wharton W, Kehoe PG, Zissimopoulos J. Association of combination statin and antihypertensive therapy with reduced Alzheimer's disease and related dementia risk. *PLoS One*. 2020;15(3):e0229541. Published 2020 Mar 4. doi:10.1371/journal.pone.0229541. [Full Text](#).

Basu, A. A welfare-theoretic model consistent with the practice of cost-effectiveness analysis and its implications. *Journal of Health Economics*. 2020 Jan 11; 70: 102287. doi: 10.1016/j.jhealeco.2020.102287. [Epub ahead of print] [Full Text](#).

Basu A, Grieve R, Pritchard D. One Size Does Not Always Fit All in Value Assessment. *The American Journal of Managed Care*. 2019 Nov 13. 2019;25(11):540-542. [Full Text](#).

** These recommendations directly influenced the latest version of the ICER Procedures for Value Assessment Framework: https://icer-review.org/announcements/2020_vaf_update/*



Berrueta M, Bardach A, Ciaponni A, Xiong X, **Stergachis A, Zaraa S**, Buekens P. Maternal and neonatal data collection systems in low- and middle-income countries: scoping review protocol. *Gates Open Research* 2020.4:18. [Full Text](#).

Cook K, Forbes SP, Adamski K, Ma JJ, Chawla A, **Garrison LP Jr**. Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A [published online ahead of print, 2020 Feb 13]. *J Med Econ*. 2020;1–12. doi:10.1080/13696998.2020.1721508. [Full Text](#).

Fenwick E, **Steuten L**, Knies S, **Basu A**, et al. Value of Information Analysis for Research Decisions-An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. *Value Health*. 2020;23(2):139–150. doi:10.1016/j.jval.2020.01.001 [Full Text](#).

Jennings R, **Guo H**, Goldin A, **Wright DR**. Cost-effectiveness of Imaging Protocols for Suspected Appendicitis. *Pediatrics*. 2020;145(2):e20191352. doi:10.1542/peds.2019-1352. [Full Text](#).

Kim DD, **Guzauskas GF, Bennette CS, Basu A, Veenstra DL, Ramsey SD, Carlson JJ**. Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment. *Pharmacoeconomics*. 2020 Feb;38(2):171-179. doi: 10.1007/s40273-019-00848-8. [Full Text](#).

Li A, **Carlson JJ**, Kuderer NM, Schaefer JK, Li S, Garcia DA, Khorana AA, Carrier M, Lyman GH. Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. *Cancer*. 2020 Jan 30. doi: 10.1002/cncr.32724. [Epub ahead of print] [Full Text](#).

Pett RG, Mancl L, Revere D, **Stergachis A**. Prescription Drug Monitoring Program Use and Utility by Washington State Pharmacists: A Mixed Methods Study. *Journal of the American Pharmacists Association*. 2019 Nov 18. pii: S1544-3191(19)30441-8. [Full Text](#).

Portnoy A, **Clark S**, Ozawa S, Jit M. The impact of vaccination on gender equity: conceptual framework and human papillomavirus (HPV) vaccine case study. *Int J Equity Health*.

2020;19(1):10. Published 2020 Jan 14. doi:10.1186/s12939-019-1090-3. [Full Text](#).

Veenstra DL, Mandelblatt J, Neumann P, **Basu A**, Peterson JF, **Ramsey SD**. Health Economics Tools and Precision Medicine: Opportunities and Challenges. Forum Health Econ Policy. 2020 Mar 5. doi: 10.1515/fhep-2019-0013. [Epub ahead of print] [Full Text](#).

ACHIEVEMENTS and ACTIVITIES:

Jonathan H. Watanabe, PharmD, Ph.D., '08, '12, was recently selected by the National Academies of Sciences, Engineering, and Medicine (NASEM) Health and Medicine Division as a member of the National Academies Forum on Drug Discovery, Development, and Translation. [READ MORE](#).

Dr. Watanabe was also [selected for a new ad hoc committee](#) of the NASEM "Implications of Discarded Weight-Based Drugs" funded by the Centers for Medicare and Medicaid Services and was [named an inaugural Distinguished Fellow of the Get the Medications Right Institute](#).

Mark Bounthavong, PharmD, MPH, PhD '18, was recently made an Associate Editor for [Substance Abuse journal \(SAj\)](#), a peer-reviewed journal that serves as the official publication of the Association for Medical Education and Research in Substance Abuse (AMERSA) in association with The International Society of Addiction Medicine (ISAM) and the International Coalition for Addiction Studies in Education (INCASE). SAj offers wide-ranging coverage for healthcare professionals, addiction specialists and others engaged in research, education, clinical care, and service delivery and evaluation. SAj has an impact factor of 2.98 in 2019 and is one of the leading journals on substance abuse research. He will be the only associate editor who is a pharmacist or health economist.

Yilin Chen, 1st year CHOICE PhD Student, was awarded a travel grant for the annual Health Technology Assessment International (HTAi) conference in Beijing, China this June. She also was selected to give a podium presentation on her abstract titled, "Cost-effectiveness Analysis of Nivolumab-Ipilimumab Combination Therapy Compared to Monotherapy in Metastatic MSI-H/dMMR Colorectal Cancer in the United States".
Congratulations, Yilin!

Anirban Basu, was invited to speak at the ISPOR Orlando 2020 Plenary Session on Wednesday, May 20, which will take a methods-based look at novel topics within value assessment.

Sean Sullivan, Professor and Dean, was invited to speak at the London School of Economics, Seminar in Pharmaceutical Policy on February 12. The title of his talk was “Pharmaceutical policy development: Is the USA headed to a European model?”

Professor and Associate Dean, **Andy Stergachis** participated in the Workshop on Maternal Immunization Against Emerging Infectious Diseases, sponsored by the Coalition for Epidemic Preparedness Innovation (CEPI) on February 12-13, 2020, London, UK.

Seven CHOICE PhD students were awarded School of Pharmacy Rubenstein Endowment Fellowships to support dissertation research, independent study projects, and cover costs of conference travel for presentations. Congratulations to the award recipients: **Elizabeth Brouwer** (5th year), **Shuxian Chen** (4th year), **Karen Guo** (3rd year), **Nathaniel Hendrix** (5th year), **Boshen Jiao** (2nd year), **Lauren Strand** (4th year), and **Yilin Chen** (1st year).

2nd Year Allergan Fellow, **Jamie Ta**, received a gold ribbon for her abstract submitted to AMCP Annual meeting in April. Her abstract is titled, “Healthcare Resource Utilization and Costs Associated with Non-Adherence and Non-Persistence to Antidepressants for Major Depressive Disorder”. Be sure to check out her poster if you will be at AMCP in Houston!

[GIVE TO THE CHOICE INSTITUTE](#)



[UW HOME](#)

[THE CHOICE INSTITUTE](#)

[CHOICE STUDENT BLOG](#)

BE BOUNDLESS
FOR WASHINGTON / FOR THE WORLD



[CONTACT US](#) | [PRIVACY](#) | [TERMS](#)

